Participating Companies

4SC AG
[VSC:DB]
€30 MM MCap
An epigenetic focused company developing small molecule drugs for the treatment of cancer and autoimmune diseases. The company’s lead compound, Resminostat, is focused on Cutaneous T Cell Lymphoma but has unpartnered assets for Hodkins Lymphona, Colorectal Cancer, and HCC. [more information]

Achilles Therapeutics
[ACHL]
$41 MM MCap
cNeT (clonal neoantigen) process builds on TILs, combined with ability to identify pt-specific clonal neoantigens and generate personalized T-cell therapies. Sep19 GBP100 million Series B w/ RA, Syncona, Forbion, Invus, Perceptive + Redmile. [more information]

Anavex Life Sciences Corp.
[AVXL]
$758 MM MCap
The lead compound ANAVEX2-73 received orphan drug designation from the FDA in Rett Syndrome, with Ph 2 trial initiating 1H2018. 2-73 is a small-molecule activator of the sigma-1 receptor which has shown capable of restoring neural cell homeostasis. The analysis of RNA and whole exome DNA genome sequencing data has characterized several genomic alterations in well-characterized targets that can be used as biomarkers to identify optimal patients in forthcoming clinical trials (Rett, Alzheimer’s, and Parkinson’s). [more information]

Apeiron Investment Group LLC
Apeiron focuses on Financial Services (especially fintech and crypto assets), Technology, Life Sciences, Media & Entertainment and Real Estate & Prop-Tech. As of 2022 circa US$ 3.5bn AUM. They invest in all phases and stages of a company’s life cycle, but focus on non-listed Seed/Start-up investments and larger size Restructuring & Special Situations deals (often listed). [more information]

Bain Capital Life Sciences
Bain Capital Life Sciences invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies globally, with a focus on companies that both drive medical innovation across the value chain and enable that innovation to improve the lives of patients with unmet medical needs. The differentiated skillset of Bain Capital’s team enables it to pursue opportunities created by several longterm trends in healthcare. In particular, these trends are creating an increased need for targeted capital and value-added strategic support of companies around their critical phases of growth, during which they must prove their clinical and business value. [more information]

BioNTech AG
[BNTX]
$26,261 MM MCap
BioNTech AG is a fully integrated biotech company which combines all building blocks of immunotherapies under one roof. Through its diversified technology platforms and in-house diagnostics and manufacturing units, BioNTech is strategically positioned to implement its lab-bench-to-market strategy. BioNTech is pioneering disruptive technologies ranging from individualized mRNA based medicines through innovative Chimeric Antigen Receptors and T-cell Receptor-based products and novel antibody checkpoint immunomodulators. [more information]

BlueStar Investment Managers SA (Onelife Advisors)
BlueStar is an asset management company headquartered in Lugano, Switzerland, specialising in managing investment funds and advising institutional clients on asset allocation, thematic investments and investment solutions. [more information]

Calliditas Therapeutics
[CALT]
$499 MM MCap
Calliditas’ common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT). [more information]

CFGI
Our clients range from pre-revenue private start-up companies to Fortune 100 public companies, including various private equity firms and their portfolio companies in all industries. We work with finance leaders during every stage of the business lifecycle to solve complex business challenges. In the life sciences industry, CFGI has been a trusted partner to companies from IPO preparation, advising on technical accounting matters, development of internal controls compliance programs, interim SEC reporting support, and valuation of IPR&D. [more information]

Crescendo Biologics
Crescendo Biologics is a clinical stage company developing T cell enhancing therapeutics.
Crescendo’s lead programme, CB307, is a CD137 (4-1BB) x PSMA bispecific. CB307’s unique format delivers tumour-specific killing, while avoiding systemic toxicity, and can be applied to a broad range of PSMA-positive cancer indications. It is designed to cause the proliferation of tumour-specific T cells, creating a safe, broad, longer-lasting anti-tumour response and will be in the clinic in early 2021. [more information]

CureVac
[CVAC]
$1,930 MM MCap
In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. [more information]

Ernst & Young
Ernst & Young Limited is a global leader in assurance, tax, transaction and advisory services. [more information]

Ethris
Ethris has developed a complete suite of novel, proprietary and best-in-class mRNA-modification, LNP formulaton, delivery and manufacturing platforms to provide highly versatile, multi-route, multi-cargo delivery options for intramuscular, inhaled or nasal administration. Ethris' rich pipeline comprises 6+ programs with 3 near-term clinical entries. [more information]

Glycostem Therapeutics
Glycostem Therapeutics is a Dutch biotech company. Glycostem Therapeutics is the trade name of the legal entity IPD Therapeutics BV, which has been established in December 2007.
Glycostem Therapeutics has developed the world's first GMP compliant NK-cell platform that is ready for industrial scale-up. [more information]

Goodwin Procter LLP
More than 1,000 corporate and litigation attorneys leverage their specific experience and assemble full-service teams to advise clients in these and adjacent industries. [more information]

H.C. Wainwright & Co., LLC
is a full-service investment bank that offers equity research services to institutional and retail investors. The firm offers corporate finance, private client, asset management and institutional sales/trading services. H.C. [more information]
Heights Capital Management, Inc.
Heights Capital Management, Inc. is a San Francisco based private equity firm specializing in private investments in public equity in emerging growth companies. [more information]

Immatics NV
[IMTX]
$827 MM MCap
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. [more information]

InflaRx N.V.
[IFRX]
$184 MM MCap
Follow-on molecule, IFX-2, in pre-clinical development for additional sub-acute, chronic inflammatory indications. [more information]

invIOs
[more information]

iOnctura
iOnctura’s drug development programs combine immune-mediated and direct anti-tumor activity to deliver molecules with superior clinical efficacy and safety in oncology. Its lead program, IOA-244, has delivered compelling clinical monotherapy efficacy and safety data in solid and hematologic malignancies and has synergistic potential with standard of care agents across tumor types. iOnctura’s second clinical program, IOA-289, is initiating dosing in a Phase 1b in first-line pancreatic cancer in 3Q22. [more information]

KBio
Creating the new generation of biologics using its plant-based platform that has demonstrated an ability to create potentially better drug candidates at a fraction of the time and cost of conventional platforms. Focused on discovering monoclonal antibodies targeting validated pathways for rare and infectious diseases and, due to the speed and accuracy of its antibody production system, is positioned well to develop fast follower therapies against validated drug targets. [more information]

Medigene AG
[MDG1:DB]
€39 MM MCap
bluebird bio collab; BLUE initiating trial w/MDG MAGEA-4 candidate in 2020. TCRs targeting HA-1 & MAGE-A1 in devt. . DC vax in ongoing Ph 1/2; final readout in 2019. [more information]

Monte Rosa Therapeutics
[GLUE]
$327 MM MCap
Multi-asset next-gen AI-driven molecular glue-based TPD platform. Lead program in Ph 1 focused on GSPT1, a key regulator and vulnerability of MYC-driven solid tumors, including lung cancer. [more information]

MorphoSys AG
[MOR]
$1,026 MM MCap
In its proprietary development segment, the company develops antibodies that concentrate on inflammatory and autoimmune diseases, as well as cancer and infectious diseases. [more information]

Nasdaq, Inc.
[NDAQ]
$28,185 MM MCap
Nasdaq's corporate services business (20%) offers listing services and related investor relations products to publicly traded companies. Through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services. [more information]

NautaDutilh
Founded in 1724, NautaDutilh has grown to become one of the largest in the Benelux with over 400 lawyers, civil law notaries and tax advisers at offices in Amsterdam, Brussels, London, Luxembourg, New York and Rotterdam. What has kept NautaDutilh relevant all these years is adaptive thinking. This subtle art is all about learning how to think instead of being taught what to think. [more information]

Nykode Therapeutics
[NYKD]
Clinical stage immunotherapy company focused on cancer and infectious disease. Modular vaccine technology targets antigens to Antigen Presenting Cells to achieve rapid, strong and long-lasting immune responses. Key programs include Ph2 proprietary HPV 16+ cervical cancer therapeutic vaccine, Ph1/2 individualized cancer neoantigen vaccine (Genentech). Significant collaborations with Regeneron and Genentech. [more information]

Oryzon Genomics
[ORY]
Targeting lysine specific demethylase 1 (LSD1, aka KDM1A). Lead CNS compound in 3 Phase 2a trials in MS, AD and basket trial. Onc compound in 2 combo Phase 2a trials in AML and SCLC. Data exp mid-2019 [more information]

Phenex Pharmaceuticals AG
Phenex is a privately held drug discovery and development company headquartered in Ludwigshafen with a major research site in Heidelberg. The biopharmaceutical company can built on fourteen years of expertise in exploring and defining innovative, potent and selective new drug candidates from small molecules. Phenex ́ R&D activities are centered around diseases of the liver / gastrointestinal tract, as well as cancer. [more information]

Priothera
Priothera is developing the orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies. [more information]

PROSION
A pharmaceutical drug discovery company with proline derived modules (ProMs) as the world’s first PRM structure mimicking building blocks. The company develops a new class of drugs and is able to address yet undruggable considered targets that are related to various indications. For its first of many use-cases, PROSION has already shown a remarkable in vivo effect of its ProM-based anti-metastatic inhibitor – both in pancreatic and breast cancer xenograft rodent models. [more information]

Silicon Valley Bank
The bank offers online and banking services, payments, deposits and fraud prevention services. In addition, the company offers investments and asset management services, credit solutions and commercial card programs and strategic advisory services, such as deal sourcing, benchmarking, strategic valuations and transaction support. Silicon Valley Bank was founded in 1983 and is headquartered in Santa Clara, California. [more information]

Solebury Strategic Communications
With almost two decades of experience in the biotechnology, pharmaceutical, medical technology and life science technology sectors, the Trout Group offers its clients the knowledge base needed to clarify investment themes and leverage key relationships for increased exposure to the proper audience. The firm’s global reach extends through a network of offices in New York, Boston, San Francisco, London, Sydney and Shanghai with contacts in all major financial centers, helping clients to connect with the right investors. [more information]

SOTIO a.s.
Developer of Active Cellular Immunotherapy (ACI) based on activated dendritic cells for the treatment of cancer and autoimmune diseases. The company operates as a biotechnology firm which develops new therapies to address unmet medical needs using its immunotherapy platform and proprietary cell-based technologies, enabling state-of-the-art immunotherapy treatment for its patients in Prague, Czech Republic. [more information]

SphingoTec GmbH
These tests allow for the diagnosis, outcome prediction, and monitoring of acute medical conditions, such as septic shock, circulatory failure, acute heart failure and acute kidney injury. SphingoTec’s first-in-class tests are made available on its proprietary whole-blood point-of-care Nexus IB10 platform for convenient and rapid testing in near-patient and laboratory settings alongside a broad portfolio of standard-of-care test for acute care. [more information]

sterna biologicals
KG is an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, and ulcerative colitis. By targeting transcription factors that play a central role in regulating Th1- and Th2-driven inflammatory mechanisms, the Company’s proprietary DNAzyme-based drug candidates can intervene with upstream inflammatory processes to address related diseases more effectively. Sterna currently has four programs in phase 2 development. [more information]

Targovax
[TRVX]
Preliminary Ph1b data of OV ONCOS-102+chemo in mesothelioma results: combo mPFS=8.4 mos. vs. control mPFS=6.8 mos.; 1L pts mPFS-8.9 mos. Upcoming milestones: updated clinical & immune data in Ph2 mesothelioma (1H20); preclinical data on next-gen OV w/ double transgenes (1H20); and clinical data from Ph1 melanoma study, part 2 with extended dosing (2H20). [more information]

Tonix Pharmaceuticals
[TNXP]
$20 MM MCap
The company is engaged in discovering, licensing, acquiring and developing drugs and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes biologics to prevent infectious diseases and small molecules and biologics to treat pain, psychiatric and addiction conditions. While the company is also developing a potential vaccine to protect against the novel coronavirus disease. [more information]

Vivoryon
[VVY:AS]
€360 MM MCap
Develops small molecule medicines that modulate the activity and stability of pathologically altered proteins. Lead candidate varoglutamstat, currently in VIVIAD EU Ph2b and VIVA-MIND US Ph2a/2b studies in Alzheimer’s disease (AD), targets all three major hallmarks of AD (Abeta pathology, tau pathology, neuroinflammation) and synaptic impairment. [more information]

Wellington Partners
Founded in 1998, Wellington Partners is a venture capital firm based in Munich, Germany. The firm seeks to invest in the early- and growth-stage technology and life science sectors. [more information]